100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43HL149554
Award Date
9/19/19
Completion Date
8/31/21
Dollars Obligated
$225K
Overview
Activity
3
Transactions
3
Subawards
Similar Awards
Federal Agency
National Heart Lung and Blood Institute
Awardee
Medosome Biotec LLC (MJJJFTJE1SB5)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Florida, USA
Update #1
Update #2
OPTIMIZATION OF RECOMBINANT PROBIOTICS FOR ORAL DELIVERY OF ACE2/ANG-(1-7
Posted 9/14/19
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
OPTIMIZATION OF RECOMBINANT PROBIOTICS FOR ORAL DELIVERY OF ACE2/ANG-(1-7 - PROJECT SUMMARY / ABSTRACT CARDIO-PULMONARY DISEASES ARE THE LEADING CAUSE OF MORBIDITY AND MORTALITY WORLDWIDE. DESPITE RECENT ADVANCES IN DRUG THERAPY AND IMPROVEMENTS IN PATIENT CARE, CARDIO-PULMONARY DISEASES REMAINS A FATAL DISEASE. ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) AND ANGIOTENSIN-1-7[ANG-(1-7)], PROTECTIVE AXIS OF THE RENIN ANGIOTENSIN SYSTEM (RAS), HAS EMERGED AS HIGHLY EFFECTIVE IN PRODUCING BENEFICIAL EFFECTS ON METABOLIC, IMMUNE AND CARDIO- PULMONARY DYSFUNCTIONS BY BLOCKING APOPTOSIS, FIBROSIS, OXIDATIVE STRESS, AND INFLAMMATION. RECENT FINDINGS FROM OUR TEAM AND OTHERS PROVIDE UNEQUIVOCAL SUPPORT THAT THE ACE2/ANG-(1-7) AXIS PLAYS A PROTECTIVE ROLE AGAINST CARDIO-PULMONARY DISEASES. HOWEVER, THE BIGGEST IMPEDIMENT TO TRANSLATE THIS FUNDAMENTAL KNOWLEDGE INTO CLINICAL APPLICATIONS FOR MANAGEMENT AND TREATMENT OF THESE DISEASES IS LARGE-SCALE PRODUCTION OF HIGH QUALITY ACE2 AND ANG-(1-7) WITH SUFFICIENT TARGET TISSUE BIOAVAILABILITY. MEDOSOME BIOTEC, LLC AND ITS RESEARCH PARTNERS AT THE UNIVERSITY OF FLORIDA HAVE IDENTIFIED A SOLUTION THAT OFFERS TREMENDOUS COMMERCIAL POTENTIAL FOR TREATING CARDIO-PULMONARY DISEASES. THE TEAM HYPOTHESIZES THAT RECOMBINANT PROBIOTICS-BASED ORAL DELIVERY OF PROTEIN THERAPEUTICS REPRESENT AN INNOVATIVE, MORE EFFICIENT AND COST-EFFECTIVE STRATEGY TO ENHANCE THIS PROTECTIVE AXIS AT BOTH CIRCULATING AND TARGET TISSUES FOR CLINICAL APPLICATION. PRELIMINARY DATA FROM OUR UF TEAM MEMBERS HAVE DEMONSTRATED THAT (1) ACE2 AND ANG-(1-7) CAN BE EFFICIENTLY EXPRESSED AND SECRETED FROM THE PROBIOTIC BACTERIUM, LACTOBACILLUS PARACASEI , AND REACH THERAPEUTIC LEVELS IN THE CIRCULATION AND TARGET TISSUES USING PLASMID VECTORS THAT CONTAIN ANTIBIOTICS RESISTANT GENE AS SELECTION MARKER; (2) ORAL ADMINISTRATION OF LACTOBACILLUS PARACASEI EXPRESSING ANG-(1-7) PREVENTED MONOCROTALINE (MCT)-INDUCED PULMONARY HYPERTENSION, GUT PATHOPHYSIOLOGY AND DYSBIOSIS. THE OVERALL OBJECTIVE OF THIS PROJECT IS TO CONSTRUCT AND CHARACTERIZE ANTIBIOTICS- MARKER FREE VECTORS FOR EXPRESSION OF ACE2 AND ANG-(1-7) IN PROBIOTICS, AND CONFIRM THEIR EFFICACY IN ANIMAL MODELS OF PULMONARY HYPERTENSION. THE COMPLETION OF THESE STUDIES WILL POSITION US TO INITIATE PHASE II STUDIES IN WHICH WE WILL CONDUCT PRECLINICAL EXPERIMENTS THAT WILL ENABLE US TO SUBMIT A COMPLETED IND APPLICATION TO THE FDA CENTER FOR BIOLOGICS. IN ADDITION, WE WILL BUILD CAPACITY FOR PRODUCING GMP GRADE MATERIAL FOR THE CLINICAL TRIALS.
$0
2/3/22
Not listed
OPTIMIZATION OF RECOMBINANT PROBIOTICS FOR ORAL DELIVERY OF ACE2/ANG-(1-7 - PROJECT SUMMARY / ABSTRACT CARDIO-PULMONARY DISEASES ARE THE LEADING CAUSE OF MORBIDITY AND MORTALITY WORLDWIDE. DESPITE RECENT ADVANCES IN DRUG THERAPY AND IMPROVEMENTS IN PATIENT CARE, CARDIO-PULMONARY DISEASES REMAINS A FATAL DISEASE. ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) AND ANGIOTENSIN-1-7[ANG-(1-7)], PROTECTIVE AXIS OF THE RENIN ANGIOTENSIN SYSTEM (RAS), HAS EMERGED AS HIGHLY EFFECTIVE IN PRODUCING BENEFICIAL EFFECTS ON METABOLIC, IMMUNE AND CARDIO- PULMONARY DYSFUNCTIONS BY BLOCKING APOPTOSIS, FIBROSIS, OXIDATIVE STRESS, AND INFLAMMATION. RECENT FINDINGS FROM OUR TEAM AND OTHERS PROVIDE UNEQUIVOCAL SUPPORT THAT THE ACE2/ANG-(1-7) AXIS PLAYS A PROTECTIVE ROLE AGAINST CARDIO-PULMONARY DISEASES. HOWEVER, THE BIGGEST IMPEDIMENT TO TRANSLATE THIS FUNDAMENTAL KNOWLEDGE INTO CLINICAL APPLICATIONS FOR MANAGEMENT AND TREATMENT OF THESE DISEASES IS LARGE-SCALE PRODUCTION OF HIGH QUALITY ACE2 AND ANG-(1-7) WITH SUFFICIENT TARGET TISSUE BIOAVAILABILITY. MEDOSOME BIOTEC, LLC AND ITS RESEARCH PARTNERS AT THE UNIVERSITY OF FLORIDA HAVE IDENTIFIED A SOLUTION THAT OFFERS TREMENDOUS COMMERCIAL POTENTIAL FOR TREATING CARDIO-PULMONARY DISEASES. THE TEAM HYPOTHESIZES THAT RECOMBINANT PROBIOTICS-BASED ORAL DELIVERY OF PROTEIN THERAPEUTICS REPRESENT AN INNOVATIVE, MORE EFFICIENT AND COST-EFFECTIVE STRATEGY TO ENHANCE THIS PROTECTIVE AXIS AT BOTH CIRCULATING AND TARGET TISSUES FOR CLINICAL APPLICATION. PRELIMINARY DATA FROM OUR UF TEAM MEMBERS HAVE DEMONSTRATED THAT (1) ACE2 AND ANG-(1-7) CAN BE EFFICIENTLY EXPRESSED AND SECRETED FROM THE PROBIOTIC BACTERIUM, LACTOBACILLUS PARACASEI , AND REACH THERAPEUTIC LEVELS IN THE CIRCULATION AND TARGET TISSUES USING PLASMID VECTORS THAT CONTAIN ANTIBIOTICS RESISTANT GENE AS SELECTION MARKER; (2) ORAL ADMINISTRATION OF LACTOBACILLUS PARACASEI EXPRESSING ANG-(1-7) PREVENTED MONOCROTALINE (MCT)-INDUCED PULMONARY HYPERTENSION, GUT PATHOPHYSIOLOGY AND DYSBIOSIS. THE OVERALL OBJECTIVE OF THIS PROJECT IS TO CONSTRUCT AND CHARACTERIZE ANTIBIOTICS- MARKER FREE VECTORS FOR EXPRESSION OF ACE2 AND ANG-(1-7) IN PROBIOTICS, AND CONFIRM THEIR EFFICACY IN ANIMAL MODELS OF PULMONARY HYPERTENSION. THE COMPLETION OF THESE STUDIES WILL POSITION US TO INITIATE PHASE II STUDIES IN WHICH WE WILL CONDUCT PRECLINICAL EXPERIMENTS THAT WILL ENABLE US TO SUBMIT A COMPLETED IND APPLICATION TO THE FDA CENTER FOR BIOLOGICS. IN ADDITION, WE WILL BUILD CAPACITY FOR PRODUCING GMP GRADE MATERIAL FOR THE CLINICAL TRIALS.
$0
2/3/22
Not listed
OPTIMIZATION OF RECOMBINANT PROBIOTICS FOR ORAL DELIVERY OF ACE2/ANG-(1-7
$225.0k
9/14/19